Catastrophic retroperitoneal hemorrhage in COVID-19 patients under anticoagulant prophylaxis

Amir Javid; Reza Kazemi; Mehdi Dehghani; Hossein Bahrami Samani

doi:10.1016/j.eucr.2021.101568

Catastrophic retroperitoneal hemorrhage in COVID-19 patients under anticoagulant prophylaxis

Urol Case Rep. 2021 May:36:101568. doi: 10.1016/j.eucr.2021.101568. Epub 2021 Jan 13.

Authors

Amir Javid¹, Reza Kazemi², Mehdi Dehghani³, Hossein Bahrami Samani³

Affiliations

¹ Department of Urology, School of Medicine, Khorshid Hospital, Isfahan University of Medical Sciences, Iran.
² Department of Urology, School of Medicine, Al-Zahra Hospital, Khorshid Hospital, Isfahan University of Medical Sciences, Iran.
³ Department of Urology, School of Medicine, Al-Zahra Hospital, Isfahan University of Medical Sciences, Iran.

Abstract

COVID-19 patients are at high risk for both capillary micro thrombi and large vessel thrombosis. Anticoagulant administration in COVID-19 patients, especially in ICU setting, is recommended by some researchers. However, clinical guidelines don't yet recommend anticoagulation therapies in therapeutic doses in these patients. In this article, we try to introduce a less known complication of heparin application in COVID-19 patients. Retroperitoneal hemorrhage when involves the psoas muscle might be deadly because of the large volume of bleeding before causing any significant alarm. It is very important to be careful in diagnosing and managing this complication.

Publication types

Case Reports